The Foundation Fighting Blindness Retinal Degeneration Fund, affiliated with an Opus Genetics director, sold 556,000 shares on September 30. The transaction was reported on October 2 and 3.
The shares sold for an average of $4.96 each. The sale totaled approximately $2.76 million.
After the sale, the foundation held 3,236,171 shares in the clinical-stage gene therapy company. The sale reduced its holdings by nearly 15%.